// STATE LEGISLATION TRACKER

California SB 816: Professions and vocations.

⚖️ MIXED for peptide users 👤 MEDIUM user impact 📜 Status: Signed

State: California
Bill: SB 816
Filed: 2023-02-17
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

California SB 816 is a broad professions-and-vocations bill that was signed into law in 2023. For the peptide ecosystem, the main relevance is pharmacy licensing: it raises or revises California fees for sterile compounding pharmacies, nonresident sterile compounding pharmacies, and outsourcing facilities, but it does not appear to change peptide prescribing, telehealth, NP or naturopathic scope, or PDMP rules.

Key Points

Compounding pharmacies serving California may face higher state licensing costs.
503B outsourcing facilities see much larger California fee exposure.
No clear change to off-label peptide prescribing authority.
No clear telehealth expansion or restriction for peptide care.
No NP or naturopathic scope change found in the bill text.

What to Watch For

Concern Higher compounding and outsourcing facility fees could be passed through as higher peptide prices.

Concern Smaller or out-of-state compounders may reassess whether California licensing is worth the cost.

Note The bill affects pharmacy licensing fees more than clinical prescribing rules.

Note The controlled-substance change appears veterinary-focused, not a CURES or peptide-patient rule.

Where the Bill Stands

SB 816 was approved by the Governor and chaptered as Chapter 723 of the Statutes of 2023.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-10-02 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws